Personalized therapeutic cocktail of wild environmental phages rescues mice from acinetobacter baumannii wound infections

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 10, 2016, Pages 5806-5816

  Regeimbal, James M ^a   Jacobs, Anna C ^b   Corey, Brendan W ^b   Henry, Matthew S ^a   Thompson, Mitchell G ^b,d   Pavlicek, Rebecca L ^a,e   Quinones, Javier ^a   Hannah, Ryan M ^c   Ghebremedhin, Meron ^a   Crane, Nicole J ^a   Zurawski, Daniel V ^b   Teneza Mora, Nimfa C ^a   Biswas, Biswajit ^a   Hall, Eric R ^a  

^a NAVAL MEDICAL RESEARCH CENTER   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c National Biodefense Analysis and Countermeasures Center   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NAMRU Asia   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; VIRULENCE FACTOR; SEWAGE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL GROWTH; BACTERIAL LOAD; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; BACTERIOPHAGE; BACTERIUM ISOLATION; BIOFILM; BIOLUMINESCENCE; COLONY FORMING UNIT; CONTROLLED STUDY; FEMALE; FOAM DRESSING; GALLERIA MELLONELLA; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; WEIGHT REDUCTION; WOUND INFECTION; ACINETOBACTER INFECTIONS; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; MICROBIOLOGY; MOTH; MULTIDRUG RESISTANCE; PATHOGENICITY; RAMAN SPECTROMETRY; SEWAGE; VIROLOGY;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANIMALS; BACTERIOPHAGES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; MICE, INBRED BALB C; MOTHS; SEWAGE; SPECTRUM ANALYSIS, RAMAN; WOUND INFECTION;

EID: 84992692826     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02877-15     Document Type: Article

References (49)

1. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1-12. http://dx.doi.org/10.1086/595011.
2. Pendleton JN, Gorman SP, Gilmore BF. 2013. Clinical relevance of the ESKAPE pathogens. Expert Rev Anti Infect Ther 11:297-308. http://dx .doi.org/10.1586/eri.13.12.
3. Murray CK, Hospenthal DR. 2008. Acinetobacter infection in the ICU. Crit Care Clin 24:237-248, vii. http://dx.doi.org/10.1016/j.ccc.2007.12 .005.
4. Calhoun JH, Murray CK, Manring MM. 2008. Multidrug-resistant organisms in military wounds from Iraq and Afghanistan. Clin Orthop Relat Res 466:1356-1362. http://dx.doi.org/10.1007/s11999-008-0212-9.
5. Crane DP, Gromov K, Li D, Soballe K, Wahnes C, Buchner H, Hilton MJ, O'Keefe RJ, Murray CK, Schwarz EM. 2009. Efficacy of colistinimpregnated beads to prevent multidrug-resistant A. baumannii implantassociated osteomyelitis. J Orthop Res 27:1008-1015. http://dx.doi.org/10.1002/jor.20847.
6. DeLeon K, Balldin F, Watters C, Hamood A, Griswold J, Sreedharan S, Rumbaugh KP. 2009. Gallium maltolate treatment eradicates Pseudomonas aeruginosa infection in thermally injured mice. Antimicrob Agents Chemother 53:1331-1337. http://dx.doi.org/10.1128/AAC.01330-08.
7. Griffith ME, Lazarus DR, Mann PB, Boger JA, Hospenthal DR, Murray CK. 2007. Acinetobacter skin carriage among US army soldiers deployed in Iraq. Infect Control Hosp Epidemiol 28:720-722. http://dx.doi.org/10 .1086/518966.
8. Hawley JS, Murray CK, Griffith ME, McElmeel ML, Fulcher LC, Hospenthal DR, Jorgensen JH. 2007. Susceptibility of Acinetobacter strains isolated from deployed U.S. military personnel. Antimicrob Agents Chemother 51:376-378. http://dx.doi.org/10.1128/AAC.00858-06.
9. Hawley JS, Murray CK, Jorgensen JH. 2007. Development of colistindependent Acinetobacter baumannii-Acinetobacter calcoaceticus complex. Antimicrob Agents Chemother 51:4529-4530. http://dx.doi.org/10 .1128/AAC.01115-07.
10. Hawley JS, Murray CK, Jorgensen JH. 2008. Colistin heteroresistance in Acinetobacter and its association with previous colistin therapy. Antimicrob Agents Chemother 52:351-352. http://dx.doi.org/10.1128/AAC .00766-07.
11. Hujer KM, Hujer AM, Hulten EA, Bajaksouzian S, Adams JM, Donskey CJ, Ecker DJ, Massire C, Eshoo MW, Sampath R, Thomson JM, Rather PN, Craft DW, Fishbain JT, Ewell AJ, Jacobs MR, Paterson DL, Bonomo RA. 2006. Analysis of antibiotic resistance genes in multidrugresistant Acinetobacter sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center. Antimicrob Agents Chemother 50:4114-4123. http://dx.doi.org/10.1128/AAC.00778-06.
12. Michalopoulos A, Falagas ME. 2010. Treatment of Acinetobacter infections. Expert Opin Pharmacother 11:779-788. http://dx.doi.org/10.1517/14656561003596350.
13. Tribble DR, Conger NG, Fraser S, Gleeson TD, Wilkins K, Antonille T, Weintrob A, Ganesan A, Gaskins LJ, Li P, Grandits G, Landrum ML, Hospenthal DR, Millar EV, Blackbourne LH, Dunne JR, Craft D, Mende K, Wortmann GW, Herlihy R, McDonald J, Murray CK. 2011. Infection-associated clinical outcomes in hospitalized medical evacuees after traumatic injury: trauma infectious disease outcome study. J Trauma 71:S33-S42. http://dx.doi.org/10.1097/TA.0b013e318221162e.
14. Yun HC, Branstetter JG, Murray CK. 2008. Osteomyelitis in military personnel wounded in Iraq and Afghanistan. J Trauma 64:S163-S168; discussion S168. http://dx.doi.org/10.1097/TA.0b013e318160868c.
15. D'Herelle F. 1917. An invisible antagonist microbe of dysentery bacillus. Compte Rendus Hebdomadaires Seances Acad Sci 165:373-375.
16. Eaton MD, Bayne-Jones S. 1934. Bacteriophage therapy. JAMA 103: 1769-1776, 1847-1853, 1934-1939. http://dx.doi.org/10.1001/jama.1934 .72750490003007.
17. Marcuk LM, Nikiforov VN, Scerbak JF, Levitov TA, Kotljarova RI, Naumsina MS, Davydov SU, Monsur KA, Rahman MA, Latif MA, Northrup RS, Cash RA, Hug I, Dey CR, Phillips RA. 1971. Clinical studies of the use of bacteriophage in the treatment of cholera. Bull World Health Organ 45:77-83.
18. Smith HW, Huggins MB. 1982. Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. J Gen Microbiol 128:307-318.
19. Soothill JS. 1992. Treatment of experimental infections of mice with bacteriophages. J Med Microbiol 37:258-261. http://dx.doi.org/10.1099/00222615-37-4-258.
20. Merril CR, Biswas B, Carlton R, Jensen NC, Creed GJ, Zullo S, Adhya S. 1996. Long-circulating bacteriophage as antibacterial agents. Proc Natl Acad Sci U S A 93:3188-3192. http://dx.doi.org/10.1073/pnas.93.8.3188.
21. Alisky J, Iczkowski K, Rapoport A, Troitsky N. 1998. Bacteriophages show promise as antimicrobial agents. J Infect 36:5-15. http://dx.doi.org/10.1016/S0163-4453(98)92874-2.
22. Biswas B, Adhya S, Washart P, Paul B, Trostel AN, Powell B, Carlton R, Merril CR. 2002. Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect Immun 70:204-210. http://dx.doi.org/10.1128/IAI.70.1.204-210.2002.
23. Merril CR, Scholl D, Adhya SL. 2003. The prospect for bacteriophage therapy in Western medicine. Nat Rev Drug Discov 2:489-497. http://dx .doi.org/10.1038/nrd1111.
24. Bruttin A, Brussow H. 2005. Human volunteers receiving Escherichia coli phage T4 orally: a safety test of phage therapy. Antimicrob Agents Chemother 49:2874-2878. http://dx.doi.org/10.1128/AAC.49.7.2874-2878.2005.
25. Rhoads DD, Wolcott RD, Kuskowski MA, Wolcott BM, Ward LS, Sulakvelidze A. 2009. Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J Wound Care 18:237-238, 240-233. http://dx.doi.org/10.12968/jowc.2009.18.6.42801.
26. Kutter E, De Vos D, Gvasalia G, Alavidze Z, Gogokhia L, Kuhl S, Abedon ST. 2010. Phage therapy in clinical practice: treatment of human infections. Curr Pharm Biotechnol 11:69-86. http://dx.doi.org/10.2174/138920110790725401.
27. Chan BK, Abedon ST, Loc-Carrillo C. 2013. Phage cocktails and the future of phage therapy. Future Microbiol 8:769-783. http://dx.doi.org/10.2217/fmb.13.47.
28. Sambrook J, Fritsch EF, Maniatis T. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Press, Cold Spring Harbor, NY.
29. Jacobs AC, Thompson MG, Black CC, Kessler JL, Clark LP, McQueary CN, Gancz HY, Corey BW, Moon JK, Si Y, Owen MT, Hallock JD, Kwak YI, Summers A, Li CZ, Rasko DA, Penwell WF, Honnold CL, Wise MC, Waterman PE, Lesho EP, Stewart RL, Actis LA, Palys TJ, Craft DW, Zurawski DV. 2014. AB5075, a highly virulent isolate of Acinetobacter baumannii, as a model strain for the evaluation of pathogenesis and antimicrobial treatments. mBio 5:e01076-14. http://dx.doi .org/10.1128/mBio.01076-14.
30. Thompson MG, Black CC, Pavlicek RL, Honnold CL, Wise MC, Alamneh YA, Moon JK, Kessler JL, Si Y, Williams R, Yildirim S, Kirkup BC, Jr, Green RK, Hall ER, Palys TJ, Zurawski DV. 2014. Validation of a novel murine wound model of Acinetobacter baumannii infection. Antimicrob Agents Chemother 58:1332-1342. http://dx.doi.org/10.1128/AAC .01944-13.
31. Kumar A, Dalton C, Cortez-Cordova J, Schweizer HP. 2010. Mini-Tn7 vectors as genetic tools for single copy gene cloning in Acinetobacter baumannii. J Microbiol Methods 82:296-300. http://dx.doi.org/10.1016/j .mimet.2010.07.002.
32. Henry M, Biswas B, Vincent L, Mokashi V, Schuch R, Bishop-Lilly KA, Sozhamannan S. 2012. Development of a high throughput assay for indirectly measuring phage growth using the OmniLogTM system. Bacteriophage 2:159-167. http://dx.doi.org/10.4161/bact.21440.
33. Luke NR, Sauberan SL, Russo TA, Beanan JM, Olson R, Loehfelm TW, Cox AD, St Michael F, Vinogradov EV, Campagnari AA. 2010. Identification and characterization of a glycosyltransferase involved in Acinetobacter baumannii lipopolysaccharide core biosynthesis. Infect Immun 78: 2017-2023. http://dx.doi.org/10.1128/IAI.00016-10.
34. Russo TA, Luke NR, Beanan JM, Olson R, Sauberan SL, Macdonald U, Schultz LW, Umland TC, Campagnari AA. 2010. The K1 capsular polysaccharide of Acinetobacter baumannii 307-0294 is a major virulence factor. Infect Immun. 78:3993-4000. http://dx.doi.org/10.1128/IAI.00366-10.
35. Peleg AY, Jara S, Monga D, Eliopoulos GM, Moellering RC, Jr, Mylonakis E. 2009. Galleria mellonella as a model system to study Acinetobacter baumannii pathogenesis and therapeutics. Antimicrob Agents Chemother 53:2605-2609. http://dx.doi.org/10.1128/AAC.01533-08.
36. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.
37. Azeredo J, Sutherland IW. 2008. The use of phages for the removal of infectious biofilms. Curr Pharm Biotechnol 9:261-266. http://dx.doi.org/10.2174/138920108785161604.
38. Bessler W, Fehmel F, Freund-Molbert E, Knufermann H, Stirm S. 1975. Escherichia coli capsule bacteriophages. IV. Free capsule depolymerase 29. J Virol 15:976-984.
39. Cornelissen A, Ceyssens PJ, T'Syen J, Van Praet H, Noben JP, Shaburova OV, Krylov VN, Volckaert G, Lavigne R. 2011. The T7-related Pseudomonas putida phage phi15 displays virion-associated biofilm degradation properties. PLoS One 6:e18597. http://dx.doi.org/10.1371/journal.pone.0018597.
40. Hughes KA, Sutherland IW, Clark J, Jones MV. 1998. Bacteriophage and associated polysaccharide depolymerases-novel tools for study of bacterial biofilms. J Appl Microbiol 85:583-590. http://dx.doi.org/10.1046/j .1365-2672.1998.853541.x.
41. Hughes KA, Sutherland IW, Jones MV. 1998. Biofilm susceptibility to bacteriophage attack: the role of phage-borne polysaccharide depolymerase. Microbiology 144:3039-3047. http://dx.doi.org/10.1099/00221287-144-11-3039.
42. Kassa T, Chhibber S. 2012. Thermal treatment of the bacteriophage lysate of Klebsiella pneumoniae B5055 as a step for the purification of capsular depolymerase enzyme. J Virol Methods 179:135-141. http://dx.doi.org/10 .1016/j.jviromet.2011.10.011.
43. Sutherland IW. 1995. Polysaccharide lyases. FEMS Microbiol Rev 16: 323-347. http://dx.doi.org/10.1111/j.1574-6976.1995.tb00179.x.
44. Linnerborg M, Weintraub A, Albert MJ, Widmalm G. 2001. Depolymerization of the capsular polysaccharide from Vibrio cholerae O139 by a lyase associated with the bacteriophage JA1. Carbohydr Res 333:263-269. http://dx.doi.org/10.1016/S0008-6215(01)00159-8.
45. Tipton KA, Dimitrova D, Rather PN. 2015. Phase-variable control of multiple phenotypes in Acinetobacter baumannii strain AB5075. J Bacteriol 197:2593-2599. http://dx.doi.org/10.1128/JB.00188-15.
46. Senchenkova SN, Shashkov AS, Popova AV, Shneider MM, Arbatsky NP, Miroshnikov KA, Volozhantsev NV, Knirel YA. 2015. Structure elucidation of the capsular polysaccharide of Acinetobacter baumannii AB5075 having the KL25 capsule biosynthesis locus. Carbohydr Res 408: 8-11. http://dx.doi.org/10.1016/j.carres.2015.02.011.
47. Naumann D. 2001. FT-infrared and FT-Raman spectroscopy in biomedical research, p 329-337. In Gremlich HU, Yan B (ed), Infrared and Raman spectroscopy of biological materials. CRC Press, New York, NY.
48. Socrates G. 2004. Infrared and Raman characteristic group frequencies: tables and charts, 3rd ed. John Wiley & Sons, Ltd, New York, NY.
49. Loh JM, Adenwalla N, Wiles S, Proft T. 2013. Galleria mellonella larvae as an infection model for group A streptococcus. Virulence 4:419-428. http://dx.doi.org/10.4161/viru.24930.